Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 18 studies | 39% ± 20% | |
peripheral blood | 10 studies | 26% ± 11% | |
lung | 9 studies | 28% ± 9% | |
eye | 8 studies | 26% ± 11% | |
bone marrow | 4 studies | 23% ± 12% | |
heart | 4 studies | 18% ± 2% | |
kidney | 4 studies | 19% ± 3% | |
adipose | 4 studies | 22% ± 2% | |
pancreas | 3 studies | 47% ± 22% | |
uterus | 3 studies | 32% ± 6% | |
intestine | 3 studies | 27% ± 9% | |
liver | 3 studies | 28% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 15873.49 | 2640 / 2642 | 100% | 191.32 | 704 / 705 |
esophagus | 100% | 9719.16 | 1444 / 1445 | 99% | 72.90 | 182 / 183 |
lung | 100% | 8262.10 | 577 / 578 | 99% | 68.87 | 1144 / 1155 |
thymus | 100% | 8476.46 | 651 / 653 | 99% | 130.19 | 598 / 605 |
breast | 100% | 9485.20 | 459 / 459 | 98% | 103.39 | 1100 / 1118 |
prostate | 100% | 7807.00 | 244 / 245 | 99% | 113.15 | 495 / 502 |
adrenal gland | 100% | 7498.64 | 258 / 258 | 98% | 149.95 | 225 / 230 |
ovary | 100% | 10114.22 | 180 / 180 | 97% | 41.22 | 419 / 430 |
kidney | 99% | 4804.01 | 88 / 89 | 97% | 110.53 | 873 / 901 |
uterus | 100% | 11612.76 | 170 / 170 | 95% | 57.21 | 434 / 459 |
skin | 100% | 7241.68 | 1801 / 1809 | 94% | 94.20 | 443 / 472 |
pancreas | 95% | 3915.08 | 313 / 328 | 97% | 68.80 | 173 / 178 |
intestine | 100% | 10009.09 | 966 / 966 | 93% | 46.75 | 488 / 527 |
stomach | 95% | 6041.94 | 341 / 359 | 95% | 54.36 | 273 / 286 |
liver | 98% | 4355.01 | 222 / 226 | 92% | 48.75 | 374 / 406 |
bladder | 100% | 11870.48 | 21 / 21 | 89% | 42.65 | 447 / 504 |
blood vessel | 100% | 17995.25 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 5787.12 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 100% | 10269.36 | 1203 / 1204 | 0% | 0 | 0 / 0 |
muscle | 99% | 5094.87 | 792 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 65.67 | 43 / 45 |
heart | 91% | 5720.38 | 786 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 87% | 6351.84 | 811 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 86% | 43.73 | 25 / 29 |
eye | 0% | 0 | 0 / 0 | 79% | 42.24 | 63 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0006954 | Biological process | inflammatory response |
GO_0045087 | Biological process | innate immune response |
GO_0007616 | Biological process | long-term memory |
GO_0046330 | Biological process | positive regulation of JNK cascade |
GO_0043030 | Biological process | regulation of macrophage activation |
GO_1900745 | Biological process | positive regulation of p38MAPK cascade |
GO_0034137 | Biological process | positive regulation of toll-like receptor 2 signaling pathway |
GO_0010738 | Biological process | regulation of protein kinase A signaling |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0005886 | Cellular component | plasma membrane |
GO_0034451 | Cellular component | centriolar satellite |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005813 | Cellular component | centrosome |
GO_0045111 | Cellular component | intermediate filament cytoskeleton |
GO_0000139 | Cellular component | Golgi membrane |
GO_0014069 | Cellular component | postsynaptic density |
GO_0005737 | Cellular component | cytoplasm |
GO_0036064 | Cellular component | ciliary basal body |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0034237 | Molecular function | protein kinase A regulatory subunit binding |
GO_0034236 | Molecular function | protein kinase A catalytic subunit binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | PJA2 |
Protein name | E3 ubiquitin-protein ligase Praja-2 (Praja2) (EC 2.3.2.27) (RING finger protein 131) (RING-type E3 ubiquitin transferase Praja-2) |
Synonyms | KIAA0438 RNF131 |
Description | FUNCTION: Has E2-dependent E3 ubiquitin-protein ligase activity . Responsible for ubiquitination of cAMP-dependent protein kinase type I and type II-alpha/beta regulatory subunits and for targeting them for proteasomal degradation. Essential for PKA-mediated long-term memory processes . Through the ubiquitination of MFHAS1, positively regulates the TLR2 signaling pathway that leads to the activation of the downstream p38 and JNK MAP kinases and promotes the polarization of macrophages toward the pro-inflammatory M1 phenotype . Plays a role in ciliogenesis by ubiquitinating OFD1 . . |
Accessions | ENST00000361189.7 [O43164-1] O43164 ENST00000361557.4 [O43164-1] |